AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Bausch Health(BHC) shares plummeted 12.95%, hitting their lowest level since July 2024, with an intraday decline of 15.34%.
The
recently adjusted its target price for Companies, reducing it from $9.00 to $8.50 and assigning a "sector perform" rating. This downgrade has the potential to influence investor sentiment and impact stock prices negatively.On a more positive note, Bausch Health has entered into a letter of intent with the pan-Canadian Pharmaceutical Alliance. This agreement aims to secure Canadian public drug plan coverage for CABTREO, a new acne treatment. The potential for increased future revenues and improved investor perception could offset some of the negative sentiment caused by the Royal Bank of Canada's downgrade.

Knowing stock market today at a glance

Dec.23 2025

Dec.23 2025

Dec.23 2025

Dec.23 2025

Dec.23 2025
Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet